Clinical Trial Update: Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder [Phase 3]

View source ↗

Summary

A Phase 3 withdrawal study evaluating the maintenance effect of tasimelteon for Non-24-Hour Sleep-Wake Disorder; the study is completed with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-24-hour Sleep-wake Disorder

Drugs mentioned

• Hetlioz (tasimelteon)

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Non-24-Hour Sleep-Wake Disorder | Phase 3 | Status: COMPLETED | Results posted: 2014-10-10